Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer
- 140 Downloads
Triple-negative breast cancer (TNBC) has been ranked as one of the devastating malignancy worldwide. Its disease progression and treatment obstacle is associated with the negligible expression of estrogen receptors (ER−), progesterone receptors (PR−), and HER2 (HER2−). Due to a lack of growth hormone receptors, TNBC is desperately demanding effective therapeutic regimens. A growing body of evidence indicated that glycoprotein 130 kDa (GP130), the pivotal mediator involved in interleukin 6 (IL-6) and signal transducer and activator of transcription 3 (STAT3) signaling pathways, is strongly correlated with tumor progression. Therefore, GP130 could become a novel target for treating TNBC. In our earlier studies, we demonstrated bazedoxifene as being a novel GP130 inhibitor.
In the current report, anti-tumor effect of bazedoxifene on TNBC was further evaluated in TNBC cell lines SUM159, MDA-MB-231, and MDA-MB-468. We assessed anti-TNBC potency of bazedoxifene by carrying out various analysis encompassing western blot, cell proliferation, cell migration, colony formation, and growth of tumors in the xenograft mice.
Our findings demonstrated that bazedoxifene not only decreased the expression of P-STAT3, IL-6/GP130-mediated downstream target genes P-AKT and P-ERK, but also blocked mitogen effects stimulated by IL-6, including cell viability, and overall cell survive, proliferation as well as cell migration. Likewise in laboratory animal model, tumor growth in mice was remarkably suppressed by bazedoxifene via an oral administration route. Combinational treatment of bazedoxifene plus the conventional chemotherapeutic agent, paclitaxel, synergistically impeded cell viability, colony formation, and cell migration far more significantly than the one from single-drug alone.
Taken together, our data suggest that bazedoxifene may be developed as a promising small molecular therapeutic agent for eradicating TNBC intrinsically associated with constitutively active IL-6/GP130/STAT3 signaling cascade.
KeywordsBazedoxifene GP130 Triple-negative breast cancer P-STAT3 Paclitaxel
JT thanks the support from China Scholarship Council.
This work was supported by the University of Maryland School of Medicine and Comprehensive Cancer Center start up fund.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All animal studies were conducted in accordance with the principles and standard procedures set off by IACUC of the University of Maryland, Baltimore, Baltimore, MD, USA.
For this type of study, formal consent is not required.
- 3.Heo T, Wahler J, Suh N (2016) Potential therapeutic implications targeting agents in breast cancer. Oncotarget 7:15460–15473Google Scholar
- 14.Li H, Xiao H, Lin L et al (2014) Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface. J Med Chem 57:632–641. https://doi.org/10.1021/jm401144z CrossRefGoogle Scholar
- 31.Kharode Y, Bodine PVN, Miller CP et al (2008) The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 149:6084–6091. https://doi.org/10.1210/en.2008-0817 CrossRefGoogle Scholar
- 36.Archer DF, Pinkerton JV, Utian WH et al (2009) Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 16:1109–1115. https://doi.org/10.1097/gme.0b013e3181a818db CrossRefGoogle Scholar
- 37.Palacios S, de Villiers TJ, Nardone FDC et al (2013) Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study. Maturitas 76:81–87. https://doi.org/10.1016/j.maturitas.2013.06.008 CrossRefGoogle Scholar
- 39.Chines AA, Komm BS (2009) Bazedoxifene acetate: a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Drugs Today 45:507–520Google Scholar
- 43.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 379:432–444. https://doi.org/10.1016/j.breastdis.2013.01.026 CrossRefGoogle Scholar
- 46.Peng L, Luo Q, Lu H (2017) Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: a systematic review and meta-analysis. Medicine (Baltimore) 96:49Google Scholar